Elaina M. Gartner
- Oncology top 5%
- Surgery top 5%
- Molecular Biology
- Immunology top 10%
- Pulmonary and Respiratory Medicine top 10%
- Co-authors
- Amal Melhem‐BertrandtDaniel P. PetrylakJonathan E. RosenbergElisabeth I. HeathPeter H. O’DonnellArjun Vasant BalarNoah M. HahnBradley A. McGregor
- Topics
- Bladder and Urothelial Cancer Treatments (19 papers)Urinary and Genital Oncology Studies (17 papers)Cancer Treatment and Pharmacology (6 papers)
- Cited by
- OncologySurgeryImmunology
- Partner nations
- United StatesCanadaSpain
In The Last Decade
Elaina M. Gartner
40 papers receiving 1.7k citations
Hit Papers
Peers
Comparison fields: 5 of 79
- Oncology 964
- Surgery 683
- Molecular Biology 430
- Immunology 302
- Pulmonary and Respiratory Medicine 281
Countries citing papers authored by Elaina M. Gartner
This map shows the geographic impact of Elaina M. Gartner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elaina M. Gartner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elaina M. Gartner more than expected).
Fields of papers citing papers by Elaina M. Gartner
This network shows the impact of papers produced by Elaina M. Gartner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elaina M. Gartner. The network helps show where Elaina M. Gartner may publish in the future.
Co-authorship network of co-authors of Elaina M. Gartner
This figure shows the co-authorship network connecting the top 25 collaborators of Elaina M. Gartner. A scholar is included among the top collaborators of Elaina M. Gartner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elaina M. Gartner. Elaina M. Gartner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 8 | |
| 2 | EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinomabreakdown → | 223 |
| 3 | 65 | |
| 4 | Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapybreakdown → | 435 |
| 5 | 57 | |
| 6 | 9 | |
| 7 | 33 | |
| 8 | 9 | |
| 9 | 97 | |
| 10 | 49 | |
| 11 | 67 | |
| 12 | 38 | |
| 13 | 53 | |
| 14 | 1 | |
| 15 | 234 | |
| 16 | 5 | |
| 17 | 27 | |
| 18 | 36 | |
| 19 | 9 | |
| 20 | 2 |
About Elaina M. Gartner
Elaina M. Gartner is a scholar working on Oncology, Biotechnology and Surgery, having authored 40 papers that have together received 1.7k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (19 papers), Urinary and Genital Oncology Studies (17 papers) and Cancer Treatment and Pharmacology (6 papers). The work is most often cited by research in Oncology (964 citations), Surgery (683 citations) and Immunology (302 citations). Elaina M. Gartner has collaborated with scholars based in United States, Canada and Spain. Frequent co-authors include Amal Melhem‐Bertrandt, Daniel P. Petrylak, Jonathan E. Rosenberg, Elisabeth I. Heath, Peter H. O’Donnell, Arjun Vasant Balar, Noah M. Hahn, Bradley A. McGregor, Evan Y. Yu and Juan Pinelli. Their work appears in journals such as Journal of Clinical Oncology, Cancer and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.